A detailed history of Price T Rowe Associates Inc transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 14,884 shares of ATXS stock, worth $175,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,884
Previous 14,203 4.79%
Holding current value
$175,928
Previous $200,000 32.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$8.83 - $13.51 $6,013 - $9,200
681 Added 4.79%
14,884 $136,000
Q1 2024

May 15, 2024

BUY
$6.99 - $16.69 $99,278 - $237,048
14,203 New
14,203 $200,000
Q4 2021

Feb 14, 2022

SELL
$5.08 - $8.62 $60,787 - $103,146
-11,966 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$7.32 - $12.9 $87,591 - $154,361
11,966 New
11,966 $106,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $179M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.